SAGE-217 was issued patent number US 9,512,165 B2, which runs to April 2034. The link to other patent applications can be found here SAGE Patent Applications. SAGE-217 is the oral version of SAGE-547, and will be running four proof-of-concept, phase 2 clinical trials in 2017. Thank you for reading.
No comments:
Post a Comment